基于临床指南的肺动脉高压住院患者用药分析及评价

Analysis and Evaluation of Medication in Hospitalized Patients with Pulmonary Hypertension Based on Clinical Guidelines

目的基于临床指南分析肺动脉高压住院患者在某心血管病专科医院的用药情况,为肺动脉高压靶向药物的临床合理使用提供参考。方法选取某院2021年诊断为肺动脉高压的住院患者数据,对其用药情况进行统计,计算药物限定日剂量(DDDs)、日用药金额(DDc)、药物利用指数(DUI)等。结果纳入研究患者1866例,肺动脉高压靶向药物销售金额排名第四,使用频次排名第八,其中DDDs最高的药物是马昔腾坦片,DDDs最小的药物是司来帕格片,DDc最高的药物是司来帕格片,DDc最低的是他达拉非片;仅他达拉非片的DUI>1。结论肺动脉高压患者用药种类繁多,经药品集中采购肺动脉高压靶向药物价格趋于合理,减轻患者经济压力,但仍有一定下降空间。

OBJECTIVE To analyze the drug use of pulmonary arterial hypertension targeted drugs in inpatients in a cardiovascular hospital based on clinical treatment guidelines,and to provide reference for the rational use of pulmonary arterial hypertension targeted drugs.METHODS The data of inpatients diagnosed with pulmonary arterial hypertension in a hospital in 2021 were selected,and their medication-related data were statistically analyzed to calculate drug-defined daily doses(DDDs),daily drug consumption(DDc),and drug utilization index(DUI),etc.RESULTS 1866 patients were included in the study.The frequency of use of targeted drugs for pulmonary hypertension ranked eighth,and the sales amount ranked fourth.Among them,the drug with the highest DDDs was maxitensin tablets,the drug with the lowest DDDs was celepaque tablets,the drug with the highest DDc was celepaque tablets,and the drug with the lowest DDc was tadalafil tablets;Only DUI of tadalafil was greater than 1.CONCLUSION PAH patients use a wide variety of drugs,and the price of targeted drugs for pulmonary arterial hypertension through centralized procurement of drugs tends to be reasonable,reducing the economic pressure of patients,but there is still some room for decline.